ライフサイエンスコーパス: phosphate-buffered saline

1 obtained compared to result obtained in PBS (phosphate buffered saline).

2 tection limit of 500 muM in water and 1mM in phosphate buffered saline.

3 via a sandwich immunoassay for human IgG in phosphate buffered saline.

4 tuses fixed overnight in 4% paraformaldehyde/phosphate buffered saline.

5 25 head and neck squamous carcinoma cells in phosphate buffered saline.

6 specific and little non-specific binding in phosphate buffered saline.

7 eached as low as 3.5x10(1)CFUmL(-1) in 0.01M phosphate-buffered saline.

8 erapy only, (c) RF hyperthermia only, or (d) phosphate-buffered saline.

9 h; sham controls received an equal volume of phosphate-buffered saline.

10 ce treated with a scrambled-sequence PPMO or phosphate-buffered saline.

11 in all groups were agitated for 3 minutes in phosphate-buffered saline.

12 /kg) for 3 weeks, while 10 controls received phosphate-buffered saline.

13 , nonpretargeted (177)Lu-IMP288 (60 MBq), or phosphate-buffered saline.

14 n 50 muL phosphate-buffered saline or 50 muL phosphate-buffered saline.

15 axane (25 mg/kg every other day, 3 doses) or phosphate-buffered saline.

16 /d), AG490, a JAK2 inhibitor (5 mg/kg/d), or phosphate-buffered saline.

17 d incubated with either 75 microM ammonia or phosphate-buffered saline.

18 incubating celecoxib and melanin in isotonic phosphate-buffered saline.

19 to the Con A concentration up to 10(-7) M in phosphate-buffered saline.

20 ith OVA, compared with controls treated with phosphate-buffered saline.

21 animal (RRV) or human (HAL1166) rotavirus or phosphate-buffered saline.

22 for culture of mammalian and yeast cells and phosphate-buffered saline.

23 and 0.69 V, as a result of the diffusion of phosphate-buffered saline.

24 omic shift of 115 nm on changing from THF to phosphate-buffered saline.

25 py alone, (c) RF hyperthermia alone, and (d) phosphate-buffered saline.

26 were intratracheally instilled with sterile phosphate-buffered saline.

27 q of (212)Pb-daratumumab instead of 11 d for phosphate-buffered saline.

28 Outflow facility for phosphate-buffered saline (0.0027 +/- 0.00036 muL/min/mm

29 in vivo compared to in vitro using agitated phosphate buffered saline +0.02% Tween 80 pH7.4, includi

30 Myocardial retention of cells suspended in phosphate-buffered saline 1 h after delivery was 17.6 +/

31 BALB/c mice received LAIV or phosphate-buffered saline 1 or 7 days before or during p

32 LAD (100 microg/mouse intraperitoneally), or phosphate buffered saline (100 microl/mouse intraperiton

33 Cys, a synthetic ligand of TLR2, or vehicle (phosphate-buffered saline) 24 h prior to Staphylococcus

34 em of acellular agarose disks and dextran in phosphate-buffered saline (3 and 70 kDa).

35 Median survival for the groups treated with phosphate-buffered saline, 6 MBq (213)Bi-IMP288, 12 MBq

36 lutathione-S-transferase (rGST)-adjuvant and phosphate-buffered saline-adjuvant served as nonvaccinat

37 The reaction was efficient in phosphate buffered saline and a wide range of biological

38 We have calibrated the sensor using phosphate buffered saline and demonstrated trace detecti

39 tion limits of 1 pM and 10 pM of thrombin in phosphate buffered saline and mimic serum solution, resp

40 at 10 and 30 pg/mL level was demonstrated in phosphate buffered saline and serum, respectively.

41 and interlaboratory measurements, samples of phosphate buffered saline and urine, spiked with differe

42 antibody pair detects PA(83) down to 1 nM in phosphate-buffered saline and 5 nM in human serum, which

43 d 2-[(131) I] exhibit good stability in both phosphate-buffered saline and blood serum.

44 t IL-22 or anti-IL-22 neutralizing antibody; phosphate-buffered saline and IgG served as respective c

45 ntly enhanced analytical performance in both phosphate-buffered saline and plasma (6-20x improvement

46 4.5 and 7.2, (2) physiologic salt solutions (phosphate-buffered saline and saline) commonly used for

47 ated mice compared to those in animals given phosphate-buffered saline and then infected with the bac

48 thod is approximately 1 IU/mL (2 nM) in both phosphate-buffered saline and urine samples, and only 0.

49 pyridine analogues were more soluble in both phosphate-buffered saline and water.

50 omers enables robust cross-linking in water, phosphate-buffered saline, and cell culture medium to af

51 be delivered in a commercial moisturizer or phosphate-buffered saline, and do not require barrier di

52 temically administered (64)CuCl2 (74 MBq) or phosphate-buffered saline, and tumor sizes were monitore

53 the animals were compared to mock-immunized (phosphate-buffered saline) animals after bacterial chall

54 ion of infection compared to mock-immunized (phosphate-buffered saline) animals.

55 .0078mg/ml of T24 (Grade III) cell lysate in phosphate buffered saline, artificial urine and human ur

56 nose-6-Phosphate (29 animals), or 100 mul of phosphate buffered saline as a placebo control (29 anima

57 lated with herpes simplex virus 1 (HSV-1) or phosphate-buffered saline as a control.

58 determinations were lower in both saline and phosphate-buffered saline as compared to vaginal fluid m

59 Mice were treated with phosphate buffered saline (as vehicle control), dexameth

60 g/kg bodyweight intraperitoneal) or vehicle (phosphate-buffered saline) as control.

61 dies of Abeta(1-40) amyloid fibrils grown in phosphate-buffered saline at 37 degrees C under unstirre

62 Release studies were conducted in phosphate-buffered saline at 37 degrees C with continuou

63 formed soluble aggregates upon dilution into phosphate-buffered saline at 37 degrees C.

64 ells were formed into pellets and covered in phosphate-buffered saline at room temperature for 56 h.

65 iae (1,500 colony-forming units) or vehicle (phosphate-buffered saline) at 3 or 60 days post-injury.

66 . cenocepacia strain BC7 suspended in either phosphate-buffered saline (BC7/PBS) or P. aeruginosa alg

67 littermates received intraperitoneal nIgM or phosphate-buffered saline/bovine serum albumin/immunoglo

68 approximately 5fg/ml for assays conducted in phosphate buffered saline buffer (PBS) and approximately

69 of 0.5-10 mL containing 5-1000 ppb TNT in a phosphate-buffered saline buffer were preconcentrated in

70 ration of TT30 were unaffected by citrate or phosphate-buffered saline buffers and indicate an elonga

71 d stability of these probes were assessed in phosphate-buffered saline, cell culture medium, rat seru

72 paB and 12 serum cytokines (p < or = .05 vs. phosphate-buffered saline challenge, except for interleu

73 s (6.1 +/- 0.5 %ID/cm(3)) when compared with phosphate-buffered saline-challenged animals (4.6 +/- 0.

74 emotherapy alone, RF hyperthermia alone, and phosphate-buffered saline, combination therapy with RF h

75 emotherapy alone, RF hyperthermia alone, and phosphate-buffered saline, combination therapy with RF h

76 et for 12 weeks, then administered rIL-19 or phosphate-buffered saline concomitant with Western diet

77 the HIV-1 RNA level in cervicovaginal fluid, phosphate-buffered saline containing 10 mM LiCl was used

78 An investigation of drug release kinetics in phosphate-buffered saline containing Tween 80 led us to

79 tumor growth compared with mice treated with phosphate-buffered saline-containing liposomes (P<0.001)

80 Afterwards, 5 x 10(5) CSCs (n = 30) or phosphate-buffered saline control (n = 15) was injected

81 dose of 20 mg/kg orally twice daily (n=7) or phosphate-buffered saline control (n=6) orally for 7 day

82 e injected with BM-MSCs, AT-MSCs, or vehicle-phosphate-buffered saline (Control) 2 weeks post-defect

83 l suspension of liposomes coated with either phosphate-buffered saline (control) or clodronate (a mac

84 s, eyes received 5 microL of either Dulbecco phosphate-buffered saline (D-PBS), 10 microM D9R, or 100

85 controlling the concentration of Dulbecco's phosphate buffered saline (DPBS) electrolyte, the double

86 bacterial endotoxin contained in Dulbecco's phosphate-buffered saline (DPBS), a cohesive OVD, and a

87 herent on a quartz substrate in a deuterated phosphate-buffered saline environment at room temperatur

88 ation of 760+/-160 pM (120+/-25 ngml(-1)) in phosphate-buffered saline, falling to 2.5+/-0.7 nM (380+

89 cross-sections of brushite cylinders aged in Phosphate Buffered Saline, Foetal Bovine Serum, Dulbecco

90 The aerosol particles were then dispersed in phosphate-buffered saline for cytotoxicity and senescenc

91 TNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffered saline for multiple cycles.

92 estoration of urothelial layers, whereas the phosphate-buffered saline group had ongoing regeneration

93 c adenocarcinoma cell line Pan02 (cancer) or phosphate-buffered saline (healthy).

94 were compared with those of single agents or phosphate-buffered saline in a Raji2R-xenograft model.

95 formed different complexes in serum than in phosphate-buffered saline in terms of both size and affi

96 nm and 25-30 nm, respectively, took place in phosphate-buffered saline, in sucrose solution, and in w

97 xhibited excellent analytical performance in phosphate buffered saline, including a NO sensitivity of

98 human amniotic mesenchymal stromal cells or phosphate-buffered saline infused intracerebroventricula

99 mucosa between the molars; and 6) group I-V: phosphate-buffered saline injected into the palatal muco

100 atment groups were compared with age-matched phosphate-buffered saline-injected control transgenic an

101 led animals receiving intravenous vehicle or phosphate-buffered saline-instilled animals receiving me

102 thogenic Escherichia coli (MG1655 strain) or phosphate-buffered saline into the urethra of mice led t

103 ol virus without insert, or control vehicle (phosphate buffered saline) intraarticularly before arthr

104 data with theoretical results suggests that phosphate-buffered saline is a good solvent for Q8 and Q

105 Mouse IgG diluted in phosphate-buffered saline is used as model target antige

106 in a complex matrix (bovine serum albumin in phosphate buffered saline) is also demonstrated through

107 nhancer of viral infection fibrils formed in phosphate buffered saline keep evolving after the initia

108 cells at room temperature or 4 degrees C in phosphate-buffered saline (labeling efficiency range, 13

109 assembly by injection from THF solution into phosphate-buffered saline led to unilamellar, monodisper

110 In phosphate buffered saline medium the actual lipophilicit

111 evels (i.e., 6-240 mg/dL) were quantified in phosphate-buffered saline medium using multivariate anal

112 ml x 15 ml) (n = 12) or mock challenged with phosphate buffered saline (n = 6).

113 othelial cells, n = 4) or control treatment (phosphate-buffered saline, n = 4) by means of imaging-gu

114 alone (200 million cells, n=5), or placebo (phosphate-buffered saline; n=5) was injected into the in

115 The models were exposed to phosphate buffered saline (negative control), triethylen

116 e injected i.p. with 50 or 250 mg/kg APAP or phosphate-buffered saline on gestation day 12.5; nonpreg

117 was observed in control mice immunized with phosphate-buffered saline only.

118 Control nonischemic limbs were injected with phosphate buffered saline or remained noninjected.

119 individuals by the oral route, mice were fed phosphate-buffered saline or 10(6)M. canettii mycobacter

120 tal fat-derived stem/stromal cells in 50 muL phosphate-buffered saline or 50 muL phosphate-buffered s

121 dium was truncated by switching the cells to phosphate-buffered saline or by the addition of antibiot

122 Phosphate-buffered saline or iPSC-w/o-c-Myc was then int

123 anti-GXM died earlier than mice treated with phosphate-buffered saline or irrelevant isotype-matched

124 (OVA) at days 0 and 12, received intranasal phosphate-buffered saline or OVA challenges at days 24,

125 sensitized by intraperitoneal injections of phosphate-buffered saline or ovalbumin (OVA) at days 0 a

126 Formaldehyde, diluted in either phosphate-buffered saline or phosphate buffer, has been

127 addressed in murine airways challenged with phosphate-buffered saline or Pseudomonas aeruginosa.

128 e, which were challenged with OVA peptide or phosphate-buffered saline or remained untreated.

129 domized to a single IV injection of vehicle (phosphate-buffered saline) or suppressor of site IQ elec

130 nction 2 weeks after transplant (hCPC versus phosphate-buffered saline, P<0.03).

131 acy increased to a higher level (~100%) when phosphate buffered saline (PBS containing 137 mM NaCl) w

132 r injections (50 microl/injection) of either phosphate buffered saline (PBS) (n = 9), human synoviocy

133 bilized antibodies on the ZnO surface in (i) phosphate buffered saline (PBS) and (ii) human serum.

134 Detection of cTnT in phosphate buffered saline (PBS) and human serum (HS) buf

135 anging from ~10(5) to 3.2 x 10(7) CFUs/mL in phosphate buffered saline (PBS) and peritoneal dialysis

136 entrations of Immunoglobulin G (IgG) in both phosphate buffered saline (PBS) and spiked in E. coli ce

137 e lateral motion with synovial fluid (SF) or phosphate buffered saline (PBS) as lubricant.

138 hest Q approximately 9300 in the bio-ambient phosphate buffered saline (PBS) as well as highest sensi

139 either Freund's incomplete adjuvant (IFA) or phosphate buffered saline (PBS) at monthly intervals.

140 rene (d(8)-PS) and SiO(2) model surfaces and phosphate buffered saline (PBS) at pH 7.4.

141 ns, and was found to be slowly degradable in phosphate buffered saline (PBS) but more rapidly degrade

142 ound to contain higher TPC, TFC and TCC than phosphate buffered saline (PBS) extracts for all the fru

143 particle loaded gels can release timolol in phosphate buffered saline (PBS) for about a month at roo

144 g was induced in one eye with glutaraldehyde/phosphate buffered saline (PBS) immersion while the othe

145 Incubation of the coated sensors in phosphate buffered saline (PBS) led to a monotonic incre

146 t between phospholipid bilayer membranes and phosphate buffered saline (PBS) medium (DMW,PBS) for 19

147 DF-1) versus a bolus application of SDF-1 in phosphate buffered saline (PBS) on wound healing was eva

148 re injected subcutaneously with bleomycin or phosphate buffered saline (PBS) once daily for 28 days.

149 tions of physiologic ionic strength, such as phosphate buffered saline (PBS) or 150 mM KCl.

150 nanoparticles was enhanced compared to DMSO/phosphate buffered saline (PBS) or albumin/PBS solutions

151 pended inside a flowing medium that contains phosphate buffered saline (PBS) or whole blood.

152 lly captured and detected HIV-1 in serum and phosphate buffered saline (PBS) samples with viral loads

153 lin analog and the other delivered a control phosphate buffered saline (PBS) solution with no insulin

154 mplification at room temperature in 30min in phosphate buffered saline (PBS) solution.

155 ther with fibrocytes, dermal fibroblasts, or phosphate buffered saline (PBS) through tail vein inject

156 Prolonged hydration in phosphate buffered saline (PBS) was found to significant

157 When phosphate buffered saline (PBS) was present in the chann

158 , we explore the effect of concentration for phosphate buffered saline (PBS), a typical ionic medium

159 anotubes were found not only to be stable to phosphate buffered saline (PBS), serum, and a variety of

160 ch resonances show high Q in the bio-ambient phosphate buffered saline (PBS).

161 ol mice were similarly injected with sterile phosphate buffered saline (PBS).

162 a control vector with no insert (AxCANI), or phosphate buffered saline (PBS).

163 that received either aqueous DSP solution or phosphate buffered saline (PBS).

164 lized on a gold film in both air and flowing phosphate buffered saline (PBS).

165 performed in physiological buffers, such as phosphate buffered saline (PBS).

166 R) at a diffusion-controlled rate in aerated phosphate buffered saline (PBS).

167 The films were shown to be stable in phosphate buffered saline (PBS).

168 ere performed at 37 degrees C in rat plasma, phosphate buffered saline (PBS, pH 7.4) and PB (pH 7.4).

169 release of 23% and 47% bound lactic acid in phosphate buffered saline (PBS, pH7.4) and acetate buffe

170 raarticular injections (50 mul/injection) of phosphate buffered saline (PBS; n = 14 rats) and human s

171 56days in various media: pH5.5, 6.5, and 7.4 phosphate buffered-saline (PBS) containing 0.02% Tween 8

172 imits ranging from 1 to 40 pg in 6 muL of 1x phosphate-buffered saline (PBS) (0.2-6 ng/mL) were achie

173 In the presence of 5 mM glucose in phosphate-buffered saline (PBS) (50 mM phosphate buffer

174 n conjunctival fibroblasts were incubated in phosphate-buffered saline (PBS) (control), MMC (0.2 mg/m

175 d in 50 mg/mL TCN solution (experimental) or phosphate-buffered saline (PBS) (control).

176 aryngeally aspirated 200 ug of WTC-PM(53) or phosphate-buffered saline (PBS) (controls).

177 of transduced human MSCs suspended in either phosphate-buffered saline (PBS) (n = 4) or matrigel (n =

178 subunit (CTB) or heat-labile toxin (LTB), or phosphate-buffered saline (PBS) alone and then challenge

179 y with buffers A, B, and C, or separately by phosphate-buffered saline (PBS) alone.

180 n of the brain with cold or room temperature phosphate-buffered saline (PBS) also caused significant

181 d -25 degrees C for at least 3 days by using phosphate-buffered saline (PBS) and cysteine/methionine-

182 determination of prohibited substances from phosphate-buffered saline (PBS) and human urine using Fe

183 The detection curves were obtained in phosphate-buffered saline (PBS) and in undiluted artific

184 ts/mouse), lipopolysaccharide (2 microg), or phosphate-buffered saline (PBS) and sacrificed mice 24 h

185 niae were treated intravenously with PFCE or phosphate-buffered saline (PBS) and then managed in eith

186 tal recoveries obtained for all compounds in phosphate-buffered saline (PBS) and urine samples owing

187 bats with one of four vaccine treatments or phosphate-buffered saline (PBS) as a control and challen

188 HDP-cyclic-CDV was suspended in phosphate-buffered saline (PBS) at 37 degrees C and form

189 es for the detection of nitric oxide (NO) in phosphate-buffered saline (PBS) at pH 7.4.

190 were injected with cultured mast cells or 1x phosphate-buffered saline (PBS) before collecting serum,

191 to ovalbumin (OVA-psigma1), psigma1 only, or phosphate-buffered saline (PBS) before oral challenge wi

192 pSHEV-1 triple mutant, wild-type pSHEV-3, or phosphate-buffered saline (PBS) buffer (n = 10).

193 CA15-3 detection was first characterized in phosphate-buffered saline (PBS) buffer and in fetal calf

194 at generated by bare carbon nanotube yarn in phosphate-buffered saline (PBS) buffer.

195 Hydrolysis in pH 5.5 Mes and pH 7.2 phosphate-buffered saline (PBS) buffers was similar, but

196 Phosphate-buffered saline (PBS) containing celecoxib-PLG

197 In phosphate-buffered saline (PBS) containing EDTA, the apo

198 -2-infected guinea pigs compared to those of phosphate-buffered saline (PBS) control-vaccinated anima

199 ignificant reduction of diarrhea compared to phosphate-buffered saline (PBS) controls (PE = 84.1%; P

200 ear in WT-infected mice did not differ from phosphate-buffered saline (PBS) controls or mice infecte

201 g) were randomly divided into three groups: phosphate-buffered saline (PBS) controls, PRARI controls

202 A plus Vaxfectin i.m. or 100 mug of DNA plus phosphate-buffered saline (PBS) i.m. using a needleless

203 in the presence of succinate, fumarate, and phosphate-buffered saline (PBS) in different cell models

204 Finally, experiments with phosphate-buffered saline (PBS) indicate that the films

205 rfusion of Adv.cmv.L-CPT1 (L-CPT1, n=15) vs. phosphate-buffered saline (PBS) infusion (PBS, n=7) or e

206 technique for cell-free virus elution using phosphate-buffered saline (PBS) may provide an alternati

207 p was intravenously injected either with 2mL phosphate-buffered saline (PBS) or 3million hUTC in PBS

208 animals used as controls were injected with phosphate-buffered saline (PBS) or GBV-B, respectively.

209 olar lavage fluids from mice inoculated with phosphate-buffered saline (PBS) or S. aureus were deplet

210 ue-Dawley rats, 2 microg rhTSG-6 in 5-microL phosphate-buffered saline (PBS) or the same volume of on

211 th a S-OIV clinical isolate concentration in phosphate-buffered saline (PBS) over a range of 18-1.8 x

212 The LK14 peptide, adsorbed from a pH 7.4 phosphate-buffered saline (PBS) solution, displayed very

213 rythrocytes at 37 degrees C for up to 24h in phosphate-buffered saline (PBS) supplemented with 0 to 5

214 lity to recover DNA from Brucella species in phosphate-buffered saline (PBS) suspension and from spik

215 plification was achieved through dilution of phosphate-buffered saline (PBS) to tune Cdl to dominate

216 ll crowd and then extracted with ~0.5 muL of phosphate-buffered saline (PBS) via pipet immediately af

217 Biliverdin (40 mg/kg) or phosphate-buffered saline (PBS) was administered either

218 As an internal control, phosphate-buffered saline (PBS) was similarly injected o

219 to 400 mg/dL or 0.10-10.34 mmol/L in 100 mM phosphate-buffered saline (PBS) without significant inte

220 Inhibition of alpha-toxin by phosphate-buffered saline (PBS), 0.1% methyl-beta-cyclod

221 Phosphate-buffered saline (PBS), 5x10(5) CD34+ cells/kg,

222 x 10(9) plaque-forming units of AdvBcl-2 in phosphate-buffered saline (PBS), AdvNull empty vector in

223 (PPSV23; Merck, Whitehouse Station, NJ), or phosphate-buffered saline (PBS), before corneal infectio

224 hat C. neoformans grown with IgM, not IgG or phosphate-buffered saline (PBS), had decreased expressio

225 reserved in diverse sample matrices, namely, phosphate-buffered saline (PBS), Middlebrook 7H9 medium

226 ibodies (mAbs) and ADCs, such as nonvolatile phosphate-buffered saline (PBS), should be replaced befo

227 tion (BDL) for 14 days and were treated with phosphate-buffered saline (PBS), UDCA, all-trans retinoi

228 were attained for all the studied probes in phosphate-buffered saline (PBS), urine, and whole blood.

229 ere surface-inoculated with P. aeruginosa in phosphate-buffered saline (PBS), while sterile PBS was u

230 Here we report that a phosphate-buffered saline (PBS)-based nucleofection meth

231 lae were found in their spleens, unlike with phosphate-buffered saline (PBS)-dosed mice, and vaccinat

232 e exhibited a dermal architecture similar to phosphate-buffered saline (PBS)-injected control and nor

233 as 2.5-fold higher than in the contralateral phosphate-buffered saline (PBS)-injected eye (n = 6 rats

234 ferritin Ab-functionalized microparticles in phosphate-buffered saline (PBS).

235 tions of VIPhyb (peptidic VIP-antagonist) or phosphate-buffered saline (PBS).

236 r 50 mg/kg per week), nontarget (NT) ASO, or phosphate-buffered saline (PBS).

237 ol mice were similarly injected with sterile phosphate-buffered saline (PBS).

238 oneal injection of either 5 g/kg of rhTrx or phosphate-buffered saline (PBS).

239 1% apoEdp, 1% trifluorothymidine (TFT), and phosphate-buffered saline (PBS).

240 ne injections of lipopolysaccharide (LPS) or phosphate-buffered saline (PBS).

241 njunctival injections of either ilomastat or phosphate-buffered saline (PBS).

242 Control mice received phosphate-buffered saline (PBS).

243 injection of 1 million human fibroblasts in phosphate-buffered saline (PBS); group 2, intravenous in

244 iRNA-21 in the range from 10 pM to 100 nM in phosphate-buffered saline (PBS); the limit of detection

245 Phosphate-buffered saline (PBS, control, n=7) or 3x10(6)

246 obiota in two frequently used batch systems: phosphate-buffered saline (PBS, oligotrophic) and basal

247 ted 24 hours after intravitreal injection of phosphate-buffered saline (PBS, vehicle) or PBS + ouabai

248 beta2-treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; FCS/PBS-treated control

249 Control animals received phosphate-buffered saline (PBS; n = 5 to 7).

250 d pigs (n = 130) in one of four groups (PRCV/phosphate-buffered saline [PBS] [n = 41], PRCV/DEX [n =

251 RMG (but not in those vaccinated with REG or phosphate-buffered saline [PBS]) after homologous or het

252 and their critical micelle concentrations in phosphate buffered saline (pH 7.4) are </=85 microg/mL.

253 ately as Hg sources in washed cell assays in phosphate buffered saline (pH 7.4), we report how cell-m

254 d as OP(*OH)) from both Fe(II) and Cu(II) in phosphate buffered saline (pH 7.40) containing ascorbic

255 reported affinity for a cryptophane host in phosphate-buffered saline (pH 7.2).

256 ry and the differential pulse voltammetry in phosphate buffered saline, pH = 7.0.

257 itro radiotracer stability was determined in phosphate-buffered saline, pH 7.4, and in challenge stud

258 99% radiochemical purity and were stable in phosphate-buffered saline, pH 7.4, for 24 h.

259 ed with either bone marrow-derived MSCs or a phosphate-buffered saline placebo via direct intraventri

260 In vehicle (phosphate-buffered saline)-pretreated mice, nonapoptotic

261 of BM cells and intramyocardial injection of phosphate-buffered saline rarely induced arrhythmias.

262 (22.1 +/- 18.6% and 5.3 +/- 3.1%, for FG and phosphate-buffered saline, respectively).

263 ily dissociated from the graft surface after phosphate-buffered saline rinsing.

264 Four groups were studied: sham and SCI plus phosphate-buffered saline (SCI + PBS), human embryonic k

265 of HCV(VLDF), compared with that mixed with phosphate-buffered saline, showing extracellular assembl

266 ysis using a short gel-filtration column and phosphate buffered saline solution as the mobile phase.

267 d detection of E. coli in buffered solution (phosphate buffered saline solution).

268 properties of the water-soluble chlorins in phosphate-buffered saline solution (pH 7.4) at room temp

269 Mice that received phosphate-buffered saline solution only were included as

270 ide, and the ECL of the 1a film was found in phosphate-buffered saline solution with TPrA.

271 performed in both well-stirred and quiescent phosphate-buffered saline solutions as well as in a 0.3%

272 eceived an intracerebral injection of either phosphate-buffered saline, the neurotoxin saporin (SAP),

273 , Neq)> decreased from approximately 0.24 in phosphate buffered saline to 0.12 in 3,300 mug/ml HA and

274 th a 15% solution of saponin and washed with phosphate buffered saline to release intact parasites.

275 versibility of PRET upon the introduction of phosphate-buffered saline to the channel.

276 wth and prolonged median survival from 13 d (phosphate-buffered saline) to 20 and 29 d for DAR2 and D

277 In the phosphate buffered saline-treated animals, human skin al

278 te in HCG-treated mice compared with that in phosphate buffered saline-treated mice.

279 3-treated P. gingivalis-infected mice versus phosphate buffered saline-treated P. gingivalis-infected

280 with parstatin compared to their respective phosphate-buffered saline-treated controls.

281 improve muscle regeneration, laminin-111 or phosphate-buffered saline-treated laminin-alpha2-deficie

282 antibody-treated animals lived, whereas 3/8 phosphate-buffered saline-treated mice died.

283 face atherosclerosis was noted compared with phosphate-buffered saline-treated mice.

284 D45(+) cells in the prostates of E. coli- or phosphate-buffered saline-treated mice.

285 m 6TG-treated primary recipients relative to phosphate-buffered saline-treated recipients.

286 rly but increased later compared to those in phosphate-buffered saline-treated, PRCV-infected pigs, c

287 Competition experiments (in 68% DMSO/phosphate buffered saline) using 1 equiv of N-phenethyl-

288 after the surgical induction of OA, LUB:1 or phosphate buffered saline vehicle was administered by in

289 Control animals were treated with a phosphate buffered saline vehicle while the other group

290 usion of either human recombinant decorin or phosphate-buffered saline (vehicle).

291 unction studies, recombinant IL-7 or control phosphate buffered saline was injected intraperitoneally

292 SEB dissolved in phosphate buffered saline was resolved to levels as low

293 LV-1h153 (1 x 10(7) plaque-forming units) or phosphate buffered saline was tested in an orthotopic mu

294 regulator PG490-88 (MRx-108; 0.75 mg/kg) or phosphate-buffered saline was administered preventilatio

295 tacept (CTLA4-Ig), etanercept (anti-TNF), or phosphate-buffered saline were given to NMRI mice intrav

296 o hundred thousand cells suspended in 20 muL phosphate-buffered saline were mixed with 200 muL Matrig

297 hat does not contain a transgene (Ad312) and phosphate-buffered saline were used as controls.

298 Given time, most of the assemblies in phosphate buffered saline will turn into elongated thin

299 er-resolution microscopy was demonstrated in phosphate-buffered saline without any reducing or oxidiz

300 to protofibrils or amyloid fibrils formed in phosphate-buffered saline without stirring at 37 degrees